Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04100148 · ClinicalTrials.gov registry record · NA

SyncAV Post-Market Trial

A NA study of Congestive Heart Failure, sponsored by Abbott Medical Devices.

Active
Registry status
NA
Development phase
1,686
Enrollment target
20
Study locations

NCT04100148: Active NA study of Congestive Heart Failure, sponsored by Abbott Medical Devices.

NCT04100148 is a NA study of Congestive Heart Failure that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 1,686 participants, above the 297-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (468% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04100148, a NA study of Congestive Heart Failure, is active but no longer recruiting, sponsored by Abbott Medical Devices.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,686 participants
Enrollment target
20
Study locations

Study Summary

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

Primary Outcome

Reduction of LVESV as a continuous variable from baseline to 12 months compared between subjects in the SyncAV and fixed AV delay arms.

Conditions Studied

Interventions

  • DEVICE SyncAV programmed ON
  • DEVICE Fixed AV delay

Study Locations (20)

California

  • Comprehensive Cardiovascular - Bakersfield
  • Cardiovascular Consultants Heart Center - Fresno
  • USC University Hospital - Los Angeles

New Jersey

  • Deborah Heart & Lung Center - Browns Mills
  • Cardiovascular Associates of the Delaware Valley - Haddon Heights
  • Lourdes Cardiology Services - Voorhees Township

Arizona

  • Arizona Cardiovascular Research Center - Phoenix
  • HonorHealth - Scottsdale

Florida

  • Shands at the University of Florida - Gainesville
  • Heart Rhythm Solutions - Hollywood

Georgia

  • Piedmont Heart Institute - Atlanta
  • Emory University Hospital - Atlanta

Alabama

  • Heart Center Research, LLC. - Huntsville

Colorado

  • Colorado Heart & Vascular, P.C. - Lakewood

Iowa

  • Iowa Heart Center - West Des Moines

Trial Details

FieldValue
Enrollment Target 1,686 participants
Start Date 2019-10-03
Est. Completion 2026-06-30
Phase NA
Abbott Medical Devices

261 total trials

What the registry record for NCT04100148 still lists

NCT04100148 is an interventional study that assigns participants to a tested intervention. Its 1,686 participants enrollment target places it among the larger protocols in the corpus, above the 297-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (468% higher).

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which SyncAV programmed ON is the first listed.

NCT04100148 names 20 study sites across 13 states, led by California, New Jersey, Arizona.

Frequently Asked Questions

What is clinical trial NCT04100148 about?

NCT04100148 is a clinical study titled "SyncAV Post-Market Trial". The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ...

What is the current status of trial NCT04100148?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,686 participants. The study started on 2019-10-03. Estimated completion is 2026-06-30.

What conditions does trial NCT04100148 study?

This clinical trial studies the following conditions: Congestive Heart Failure.

What interventions are being tested in trial NCT04100148?

The interventions under investigation include: SyncAV programmed ON (DEVICE), Fixed AV delay (DEVICE).

Who is sponsoring clinical trial NCT04100148?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04100148 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congestive Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04100148's enrollment target sits among peer trials

1,686 3rd of 51 higher than 49 of 51 other Congestive Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06376565 · 1,680 participants · NA

    Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

  • NCT04321200 · 1,700 participants

    PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability

  • NCT06238622 · 1,700 participants · Phase 3

    A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  • NCT07284901 · 1,700 participants · Phase 3

    Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04100148, the US trial registry maintained by the National Library of Medicine. NCT04100148 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.